CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREA

NCT06927648 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2026-05-19

No results posted yet for this study

Summary

To fulfil the post-approval commitment of MFDS to conduct post-marketing surveillance, this study is designed to assess the known safety profile, identify previously unsuspected adverse reactions and to evaluate the effectiveness of Capivasertib under conditions of routine daily medical practice in Korea.

Conditions

Sponsors & Collaborators

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-15
Primary Completion
2029-12-30
Completion
2029-12-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06927648 on ClinicalTrials.gov